PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

Item
http://www.wikidata.org/entity/Q40248595
Genetic susceptibility to distinct bladder cancer subphenotypesUnderstanding the molecular pathogenesis and prognostics of bladder cancer: an overviewNormal and neoplastic urothelial stem cells: getting to the root of the problemMutational analysis of merkel cell carcinomaEmerging critical role of molecular testing in diagnostic genitourinary pathologyInvasive Bladder Cancer: Genomic Insights and Therapeutic PromiseOncogenic mutations of PIK3CA in human cancersPredicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis.CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA genePhosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancerFGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.Phosphorylated p70S6K in noninvasive low-grade urothelial carcinoma of the bladder: correlation with tumor recurrence.Activation of the PI3K/AKT pathway in Merkel cell carcinomaMultiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumorsFGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx.ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.Identification of mutations in distinct regions of p85 alpha in urothelial cancer.Molecular biology of bladder cancer.Novel molecular targets for urothelial carcinomaThe UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.Personalized therapy for urothelial cancer: review of the clinical evidence.PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.Bladder cancer: a simple model becomes complex.Genomic Characterization of Upper Tract Urothelial CarcinomaAutophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cellsSpectrum of genetic mutations in de novo PUNLMP of the urinary bladder.The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN.Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing.Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic targetClinical states model for biomarkers in bladder cancerNovel therapeutic targets in bladder cancer: mutation and expression of FGF receptors.Bladder cancer subtypes defined by genomic alterations.Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk.Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.Contemporary management of low-risk bladder cancer.
P2860
Q24624419-33CE20BA-A930-4797-8491-B38CBB1BA425Q26752921-2EB5826F-FC64-4D6B-9EAD-6025D1B08048Q26825948-F7513605-A013-4C10-85F8-AC28808C4C6FQ27021034-628433A7-2F21-4EDE-98D9-8B1E7597D20EQ27021371-7D307C18-BACB-497A-B4E7-6787BDFD2170Q28088334-2EA02C3B-45C9-4F6C-8D40-850C1E50F116Q28284802-CE734643-E35B-446F-8F2C-769AE526649BQ30446429-31648089-A904-4AC0-AFF2-D2718FF32A9CQ31120339-B0F79802-FF9C-46A1-A98A-0846CE001FACQ33436440-457D6614-7BF4-4C8B-A279-1F5C75058C6FQ33554443-AD272240-B0AB-4738-A48D-89988474A728Q33745140-1FB235F6-2212-4877-89D4-5358631620E7Q33886553-2729F0C1-8C07-4B78-82F6-EAB63C416FBCQ33922437-5C3C875B-2CAF-491B-86BF-0073D70D1003Q34170708-07E7C563-73F2-42C0-9F1D-C6B64A31439DQ34375736-E3470AD3-293F-4127-8CA3-7041D0DC357FQ34505851-78791AEF-9754-4C10-9630-E1F8A3B6B02DQ34708383-D26DB405-6077-4023-9ECD-73E13EC255E4Q35075756-0CC86E3D-58C6-4B58-B5BA-9067B217B918Q35266400-E7F83935-0D96-412A-BC6D-D5ED8B8C328DQ35527068-D1E13531-8AA5-4C26-B794-B9DE91C4D37FQ35638497-EF7FB834-AA15-4A85-BAA2-AC6EF840A091Q35941204-7D1A9CE0-8385-4682-B32C-28B898CEB76AQ36062762-0EC65369-9488-45C0-B9C0-C8EB6ABA38E9Q36087843-1099C4BB-8884-4DED-804B-913D1E86EE55Q36108115-446E2A3A-9173-4A98-97C8-AA0D180D1250Q36362571-B4DE7D25-8700-4D4A-B2C6-1DFC013BF7B7Q36384361-6566FB97-6A90-40C8-8697-D281E858BD10Q36396486-2CCD5C09-AB64-4D51-B116-A52DE368FC1CQ36536455-8F7AE827-A1A3-4DCB-A595-2975924761A6Q36771895-58592115-9E83-4246-A324-AEDE73EF2535Q36958930-0DA6DBDD-AEF2-4CB0-9FBD-B1B92C61FD3DQ36995765-2DEF54AC-E19C-431C-8F39-DBD4ECA6EC0CQ37074139-6BDB22DA-45F8-425F-BA88-C0BE5FFB367AQ37278990-E6573124-1E81-4A88-B366-C54227C30680Q37341453-11630444-9E3D-4FAA-872E-163E6D350056Q37612632-D725B26C-E0C2-4D99-993B-84453E86EDC7Q37711685-3967B4E6-6CF5-497C-A47A-ABFF84E99F7AQ37775890-262696C3-AB5B-4B46-86CA-3EBD9D9AC026Q37828064-7C50D6E5-C1B1-457C-AAB2-E662438B3BF4
P2860

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

Item
http://www.wikidata.org/entity/Q40248595
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
PIK3CA mutations are an early ...... cial papillary bladder tumors.
@en
type
label
PIK3CA mutations are an early ...... cial papillary bladder tumors.
@en
prefLabel
PIK3CA mutations are an early ...... cial papillary bladder tumors.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P4510
P478
P50
P577
P698
P921
P356
P1433
P1476
PIK3CA mutations are an early ...... icial papillary bladder tumors
@en
P2093
P304
P31
P356
10.1158/0008-5472.CAN-06-1182
P407
P433
P4510
P478
P50
P577
P698
P921